Fighting for affordable medicines

WE have doubts over the preliminary findings of the Cost-Benefit Assessment (CBA) 2.0 on the impact of the Medicines Price Regulation (MPR) policy, which were opened for public consultation recently (Nov 29 and Dec 6).

Although the study summary stated that patient advocacy groups had been approached for “expert views”, none of our societies were invited.

Subscribe now to our Premium Plan for an ad-free and unlimited reading experience!

Next In Letters

New OSHA alert for SMEs
Moulding graduates to meet needs of industry
Apathy and corruption facilitate illegal wildlife trade
A leap for public health
Contraflow system for roads during holidays
Education Ministry must be more inclusive
The role of KDCA in preserving tradition and fostering unity in Sabah
Building public awareness
Prioritise care and compassion in reforms
We need food, not nicotine addiction

Others Also Read